Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Chemotherapy for Early Triple-Negative Breast Cancer
NCT03036488Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2017
- Primary completion
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in triple-negative breast cancer (TNBC) comparing Pembrolizumab + Chemotherapy with Placebo + Chemotherapy (2 arms). Primary endpoints: Pathological Complete Response Rate (ypT0/Tis ypN0) and Event-free Survival at 102 months. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03036488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03036488.